drugset / Trial / NCT07587710

A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function

NCT07587710

Phase 1 Not yet recruiting 35 enrolled Novo Nordisk A/S
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study is testing a new study medicine to treat people with overweight/obesity and type 2 diabetes. The aim of this study is to see if it is safe and to find out how it works in people with reduced liver function and people with normal liver function.

Timeline

Start
2026-05-13
Primary completion
2027-12-01
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0487-0111 Unknown Subcutaneous

Indications